Novartis’ biosimilar rituximab delayed in US
Novartis’ Sandoz division announced today that the US FDA has issued a complete response letter regarding the Biologics Licensing Application (BLA)
Read moreNovartis’ Sandoz division announced today that the US FDA has issued a complete response letter regarding the Biologics Licensing Application (BLA)
Read more